Nrf2-dependent and -independent responses to nitro-fatty acids in human endothelial cells identification of heat shock response as the major pathway activated by nitro-eleic acid by Kansanen, E. et al.
Nrf2-dependent and -independent Responses to Nitro-fatty
Acids in Human Endothelial Cells
IDENTIFICATIONOFHEAT SHOCK RESPONSE AS THEMAJOR PATHWAY ACTIVATED BY
NITRO-OLEIC ACID*□S
Received for publication, September 11, 2009, and in revised form, October 2, 2009 Published, JBC Papers in Press,October 5, 2009, DOI 10.1074/jbc.M109.064873
Emilia Kansanen‡, Henna-Kaisa Jyrkka¨nen‡, Oscar L. Volger§, Hanna Leinonen‡, Annukka M. Kivela¨‡,
Sanna-Kaisa Ha¨kkinen‡, Steven R. Woodcock¶, Francisco J. Schopfer¶, Anton J. Horrevoets§, Seppo Yla¨-Herttuala‡,
Bruce A. Freeman¶1, and Anna-Liisa Levonen‡2
From the ‡Department of Biotechnology andMolecular Medicine, A. I. Virtanen Institute for Molecular Sciences, University of
Kuopio, FIN-70211 Kuopio, Finland, the §Department of Molecular Cell Biology and Immunology, VU University Medical Center,
1081 BT Amsterdam, The Netherlands, and the ¶Department of Pharmacology and Chemical Biology, University of Pittsburgh,
Pittsburgh, Pennsylvania 15213
Electrophilic fatty acid derivatives, including nitrolinoleic
acid and nitro-oleic acid (OA-NO2), can mediate anti-inflam-
matory and pro-survival signaling reactions. The transcription
factor Nrf2, activated by electrophilic fatty acids, suppresses
redox-sensitive pro-inflammatory gene expression and protects
against vascular endothelial oxidative injury. It was therefore
postulated that activation of Nrf2 by OA-NO2 accounts in part
for its anti-inflammatory actions, motivating the characteriza-
tion ofNrf2-dependent and -independent effects ofOA-NO2 on
gene expression using genome-wide transcriptional profiling.
Control and Nrf2-small interfering RNA-transfected human
endothelial cells were treated with vehicle, oleic acid, or OA-
NO2, and differential gene expression profiles were determined.
AlthoughOA-NO2 significantly induced the expression ofNrf2-
dependent genes, including heme oxygenase-1 and glutamate-
cysteine ligase modifier subunit, the majority of OA-NO2-regu-
lated genes were regulated by Nrf2-independent pathways.
Moreover, gene set enrichment analysis revealed that the heat
shock response is themajor pathway activated byOA-NO2, with
robust induction of a number of heat shock genes regulated by
the heat shock transcription factor. Inasmuch as the heat shock
response mediates anti-inflammatory and cytoprotective ac-
tions, this mechanism is proposed to contribute to the protec-
tive cell signaling functions of nitro-fatty acids and other elec-
trophilic fatty acid derivatives.
Nitration products of unsaturated fatty acids are formed
via NO-dependent oxidative reactions (1) in inflammation
(2, 3). Nitroalkene derivatives of linoleic acid (nitrolinoleic
acid, LNO2)3 and oleic acid (nitro-oleic acid, OA-NO2)
mediate pluripotent cell signaling actions, many of which
are attributed to their electrophilic nature. Nitroalkenes
undergo covalent, thiol-reversible reactions with cysteine
and histidine residues in proteins such as glyceraldehyde-3-
phosphate dehydrogenase (4) as well as with low molecular
weight thiols (5, 6). Post-translational modification of signaling
proteins by nitroalkenes mediates a component of observed
anti-inflammatory actions. For example, LNO2 and OA-NO2
inhibit nuclear factor-B (NF-B) signaling via inhibiting p65
DNAbinding and suppression of pro-inflammatory target gene
expression in monocytes and human endothelial cells (7). Inhi-
bition of p65 also contributes to the protective actions of OA-
NO2 in focal cardiac ischemia and reperfusion (3). NF-B inhi-
bition is a property shared by other electrophilic lipid oxidation
products, including 15-deoxy-12,14-prostaglandin J2 (8).
Moreover, nitroalkene fatty acid derivatives induce the expres-
sion of heme oxygenase-1 (HO-1,HMOX1), an important cyto-
protective and anti-inflammatory gene, via a peroxisome pro-
liferator-activated receptor -independent mechanism in
human endothelial cells (9).
In addition to inhibiting inflammatory signaling, electro-
philic lipid oxidation products such as 15-deoxy-12,14-
prostaglandin J2 and 4-hydroxynonenal, as well as the ni-
troalkene LNO2, activate nuclear factor E2-related factor 2
(Nrf2), a member of the cap ‘n’ collar family of basic region-
leucine zipper transcription factors and a mediator of anti-
oxidant and phase II detoxifying enzyme expression (10, 11).
Upon electrophile exposure, Nrf2 protein stabilizes, translo-
cates to the nucleus, heterodimerizes with other basic region-
leucine zipper transcription factors (preferentially small Maf
proteins), and binds to the antioxidant-response element
(ARE), a common regulatory element found in the promoter
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regions of antioxidant and detoxication enzymes (12). Activity
of Nrf2 is tightly regulated by Keap1 (Kelch-like ECH-associ-
ated protein 1), which binds to Nrf2 and directs it to Cullin-3-
dependent ubiquitination and proteosomal degradation under
homeostatic conditions. Upon exposure to electrophiles, reac-
tiveKeap1 thiols are adducted, dissociatingNrf2 fromubiquitin
E3 ligase complex and facilitating nuclear accumulation and
downstream effects on gene transcription (12).
Nrf2 regulation of antioxidant and phase II enzymes under-
scores a broader impact on the regulation of inflammatory
processes. Nrf2-deficient mice display more pronounced in-
flammation in cigarette smoke-induced emphysema than wild
type mice (13) and an increased susceptibility to severe airway
inflammation and asthma (14). Moreover, Nrf2 is a critical reg-
ulator of innate immune response in sepsis (15). Interestingly,
15-deoxy-12,14-prostaglandin J2 attenuates acute inflamma-
tion in a carrageenan-induced pleurisy model in wild type, but
not Nrf2-deficient, mice (16). From a cardiovascular perspec-
tive, vascular endothelial cell overexpression of Nrf2 inhibits
tumor necrosis factor--induced expression of the proinflam-
matory mediators VCAM-1 (vascular cell adhesion mole-
cule-1) and MCP-1 (monocyte chemotactic protein-1) (17).
Nrf2 is also activated by atheroprotective laminar flow (18–21).
Finally, in vivo gene transfer of Nrf2 reduces inflammation in
the balloon-denuded rabbit artery (22).
In addition to the ARE-regulated stress response, cells have
other integrated stress-response pathways triggered by endog-
enous stimuli or environmental stresses. The heat shock re-
sponse (HSR) is an ordered response to a wide array of acute
and chronic stress conditions.HSR is regulated at the transcrip-
tional level by heat shock factors (HSF). Upon activation, HSF
undergoes multistep processing involving post-translational
modifications, nuclear enrichment, trimerization, and binding
to heat shock elements resulting in transcription of a large fam-
ily of heat shock genes. Many of the proteins encoded by heat
shock genes function as chaperones, proteases, or other pro-
teins essential for protection of the cell against proteotoxic
stress (23).
The notion that both nitroalkene fatty acid derivatives and
Nrf2 display anti-inflammatory effects motivated the hypothe-
sis that the immune modulatory actions of nitro-fatty acids are
largely attributable to Nrf2. We thus determined the gene
expression profile of human endothelial cells exposed to OA-
NO2, and we evaluated Nrf2-dependent and -independent
effects by genome-wide transcriptional profiling of cells trans-
fected with Nrf2-specific or control siRNA. The results reveal
that Nrf2 plays only a minor role in the gene regulation medi-
ated byOA-NO2, with the heat shock response being themajor
activated pathway.
EXPERIMENTAL PROCEDURES
Reagents—OA-NO2 was prepared as described previously
(24). The synthetic nitration product of OA-NO2 used in the
study was an equimolar distribution of 9- and 10-nitro-octa-
deca-9-enoic acid (supplemental Fig. S1).
Cell Culture—Human umbilical vein endothelial cells
(HUVECs) were isolated from umbilical cords obtained from
the maternity ward of the Kuopio University Hospital by the
approval of the Kuopio University Hospital Ethics Committee.
HUVECs were cultivated as described previously (10).
siRNA—siRNA oligonucleotides targeting Nrf2, HSF1, and a
nonspecific RNA control were obtained from Invitrogen. Four
specific siRNA sequences targeting Nrf2 and twoHSF1 siRNAs
were tested prior to experimentation. The sequences of the
most efficient siRNAs were as follows: Nrf2, 5-UGA CAG
AAG UU GAC AAU UA-3, and HSF1, 5-GCT CAT TCA
GTT CCT GAT CTT-3. For the experiments, HUVECs were
seeded on 6-well plates or 10-cmplates at the density of 150,000
or 900,000 cells/well, respectively, and allowed to adhere for
24 h. Cells were transfected with 50 or 100 nM siRNA oligonu-
cleotides using Oligofectamine (Invitrogen) for 24, 48, or 72 h.
Cells were treated withOA-NO2 or OA for up to 48 h for quan-
titative real time PCR, Western blot, or Affymetrix analyses.
RNA Isolation and Quantitative Real Time PCR—HUVECs
were collected and RNA extracted with TRI Reagent (Sigma).
For the cDNA synthesis, 1 g of total RNA was used using
randomhexamer primers (Promega) andMoloney-murine leu-
kemia virus reverse transcriptase (Finnzymes). The relative
expression levels of Nrf2 (NFE2L2), HO-1 (HMOX1), GCLM,
NQO1, HSPA1A, DNAJA4, HSPB8, HSPA6, and HSF1 mRNA
in HUVECs were measured according to the manufacturer’s
protocol with quantitative real time PCR (ABI PRISM 7700
sequence detector, Applied Biosystems) using specific assays-
on-demand (Applied Biosystems) target mixes. The expression
levels were normalized to 2-microglobulin expression and
presented as fold change in the expression versus control.
Western Blotting—Cells were lysed, and total protein con-
centration was measured with BCA assay (Pierce). Nuclear
and cytoplasmic fractions were isolated with NE-PER cyto-
plasmic and nuclear extraction reagents (Pierce). For electro-
phoresis, 10 g of protein was used. The proteins were electro-
phoresed on a Tris/glycine SDS-polyacrylamide gel and
transferred to nitrocellulose membrane. The primary antibod-
ies used for detection were rabbit polyclonal anti-HO-1 (Assay
Designs), anti-GCLM (10) (a gift from Dr. Terrance Kavanagh,
University of Washington, Seattle), mouse monoclonal anti-
NQO1 (clones A180 and B771, gifts from Dr. David Ross, Uni-
versity of Colorado, Denver), rabbit polyclonal anti-Nrf2 (Santa
Cruz Biotechnology), rabbit polyclonal anti-lamin B1 (Abcam),
anti-Hsp70 (Assay Designs), and anti-HSF1 (Cell Signaling)
Blots were visualized using horseradish peroxidase-conjugated
secondary antibodies and ECL Plus detection system (GE
Healthcare) and detected with Typhoon 9400 (GE Healthcare)
scanner. Protein expression was quantified with ImageQuant
TL 7.0 software (GE Healthcare).
Chromatin Immunoprecipitation—Chromatin immunopre-
cipitation was done as described previously (25). For immuno-
precipitation against HSF1, the anti-HSF1 antibody (Cell Sig-
naling) was used. The forward and reverse primers used for
PCR amplification were as follows: HSP70 forward, 5-CCA
TGG AGA CCA ACA CC CT-3, and reverse, 5-CCC TGG
GCT TTT ATA AGT CG-3; -actin forward, 5-AAC TCT
CCC TCC TCC TCT TCC TC-3, and reverse, 5-GAG CCA
TAA AAG GCA ACT TTC GG-3.
Statistical Analysis—Statistical analysis was performed with
GraphPad Prism, and the data were analyzed by one-way
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ANOVA with Bonferroni’s post hoc comparisons. Data are
expressed as means  S.E., and differences were considered
significant at p 0.05.
Microarray Analysis—For the microarray experiment, HUVECs
pooled from three separate donors were transfected with 50
nM Nrf2-siRNA or a nonspecific control siRNA using Oligo-
fectamine (Invitrogen). After 24 h, cells were treated with
methanol (vehicle), 3 M OA, or 3 M OA-NO2 for 8 h.
Triplicate samples were used. Total RNA was extracted with
TRI Reagent (Sigma) according to themanufacturer’s instruc-
tions. The amounts and purity of total RNAs were measured
with NanoDrop ND-1000 spectrophotometer (NanoDrop
Technologies Inc., Wilmington, DE). The probes for gene
expression analysis were made according to the Affymetrix
protocol. Briefly, total RNA was reverse-transcribed to double
strand cDNA. The double strand cDNA was purified and tran-
scribed in vitro to biotin-labeled cRNA. Twenty micrograms of
purified cRNA were fragmented, and the fragmentation was
checked on agarose gel electrophoresis. The cRNAwas hybrid-
ized to Human Genome U133 Plus 2.0 GeneChips (Affymetrix,
Santa Clara, CA). The chips were stained, washed (Affymetrix
Fluidics Station 400), and scanned (AffymetrixGeneChip Scan-
ner 3000) according to the manufacturer’s protocol.
Microarray Data Handling and Statistics—Microarray data
were extracted from the scanned images by usingMAS 5.1 soft-
ware (Affymetrix). GeneChip operating software (Affymetrix)
was used to generate CEL files. Quantile inter-array data nor-
malization was carried out using CARMAweb (26). Primary
statistical comparisons were done by using a Bayesian one-way
ANOVAwith post hoc Tukey HSD (R/Bioconductor) (27), and
p values were corrected for multiple testing by the Benjamini/
Hochberg false discovery rate method (28). Criteria for signifi-
cance are as follows: false discovery rate (Benjamini/Hochberg)
5%; post hoc p value 0.05; and 1.5-fold intensity differ-
ences between different treatment groups. Gene set enrich-
ment analysis software (GSEA version 2.0) (29, 30) was used for
analysis of enrichment of transcription factor-binding sites
(TRANSFAC 7.4) in promoters of differentially expressed
genes.
RESULTS
OA-NO2 Induces HO-1, GCLM, and NQO1mRNA and Protein
Expression in Human Endothelial Cells
LNO2 induces HO-1, a well characterized Nrf2 target gene,
in endothelial cells (9). To determine whether the more stable
mono-unsaturatedOA-NO2 also inducesHO-1 as well as other
ARE-regulated genes, including the glutamate-cysteine ligase
modifier subunit (GCLM) and NAD(P)H:quinone oxidoreduc-
tase-1 (NQO1), HUVECs were treated with 0–5 M OA-NO2
for 8 h, and target gene expression was determined via quanti-
tative real time PCR. OA-NO2 induced the mRNA expression
of all three genes in a dose-dependent manner. The induction
of GCLM and NQO1 by 3 M OA-NO2 was not statistically
significant (Fig. 1A). However, in another set of experiments, in
which the time-dependent changes in gene expression was
assessed, 3 M OA-NO2 significantly induced all three genes
after 8 h, with the induction of NQO1 occurring later and sus-
taining longer than the other two genes (Fig. 1B). The discrep-
ancy is likely due to donor-specific differences in gene expres-
sion obtained from a single donor. OA-NO2 also induced
HO-1, GCLM, andNQO1protein in a dose-dependentmanner
(Fig. 1C). The maximum induction was observed at 12 h for
HO-1 and at 24 h for GCLM and NQO1 (Fig. 1D).
Induction of HO-1, GCLM, and NQO1 by OA-NO2 Is
Nrf2-dependent
Having established the optimal time and concentration for
the induction of HO-1, GCLM, and NQO1 by OA-NO2, the
role of Nrf2 in the regulation of these genes was examined
using siRNA to inhibit Nrf2 expression. Optimal siRNA con-
centration and transfection times were established, and it was
observed that transfection with 50 nM Nrf2-specific siRNA for
24 h resulted in 85% silencing of Nrf2 mRNA expression and
89% silencing at the protein level under basal conditions, with
no further suppression at higher siRNA concentrations or lon-
ger transfection times. (Fig. 2, A and B, and results not shown).
Moreover, control or Nrf2-specific siRNA did not cause an
interferon response, assessed by 2,5-oligoadenylate synthe-
tase 2 (OAS) and interferon-induced protein with tetratrico-
peptide repeats 1 (IFIT1) mRNA expression (results not
shown). Both OA-NO2-inducible mRNA and protein expres-
sion ofHO-1,GCLM, andNQO1were significantly inhibited in
FIGURE 1. OA-NO2 induces HO-1, GCLM, and NQO1 expression. HUVECs
were treated with 0–5M OA-NO2 for 8 h (A) or 16 h (C) or with 3M OA-NO2
for 0–48 h (B andD). The expression of HO-1, GCLM, and NQO1was analyzed
with quantitative real time PCR (A and B) and Western blot (C and D). Values
are expressed asmean S.E., (n 3). *, p 0.05 versus control. Western blots
are representative of three independent experiments.
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cells transfected with Nrf2-siRNA (Fig. 2, A and C). To fur-
ther validate that OA-NO2 activates ARE-dependent genes,
the NQO1 ARE luciferase reporter vector and a vector in
which the core ARE was mutated (25) were transfected into
HUVECs, and luciferase activity was assessed. OA-NO2, but
not OA, activated the ARE of the NQO1 gene (supplemental
Fig. S2A). Luciferase expression was abolished when the core
ARE was mutated (supplemental S2A). Chromatin immuno-
precipitation supported the binding of Nrf2 to the NQO1
and HO-1 promoters. Treatment with OA-NO2 increased
Nrf2 binding to theNQO1 promoter area 477 bp upstream of
the transcription start site-containing canonical ARE site
(31) as well as the distal enhancer region of HO-1 gene that
contains multiple antioxidant-response-like elements (sup-
plemental Fig. S2B) (32).
Microarray Transcriptome Analyses
Primary Statistics—To gain insight into the effect of OA-
NO2on the global gene expression profile in human endothelial
cells and to more incisively define the role of Nrf2 in mediating
these effects, we employed genome-wide transcriptional profil-
ing of cells transfected with either control or Nrf2-specific
siRNA and then exposed to vehicle, 3 M OA, or OA-NO2 for
8 h. Under all conditions, no differences in cell injury or mor-
phology were detected (data not shown). Initial transcriptome
analyses comparing OA-NO2-treated cells with OA-treated
and untreated cells revealed that mRNA expression levels were
altered byOA-NO2 treatmentwith a high degree of significance
(supplemental Table S1). Of these genes, 363 genes were up-
regulated and 103 were down-regulated by OA-NO2. Hierar-
chical clustering analysis of the mRNA expression (Fig. 3A)
illustrated thatOA-NO2 specifically
altered the expression of these
genes, whereas OA had no effect. Of
significance, within a sub-cluster of
50 genes with an elevated mRNA
expression afterOA-NO2 treatment
(Fig. 3B and supplemental Table
S1), eight of the genes with the
greatest induction were heat shock
proteins.
Role of Nrf2 in Mediating OA-
NO2-dependent Gene Expression—
To assess the role of Nrf2 in gene
expression changes evoked by OA-
NO2, differential gene expression of
OA-NO2-induced versus siNrf2-si-
lencedHUVECswas compared (Fig.
4). In all treatment groups com-
bined, silencing of Nrf2 by siRNA
resulted in 78% down-regulation of
Nrf2 mRNA (supplemental Fig. S3).
Of the two datasets, only 43 genes
were overlapping, 31 of which were
up-regulated by OA-NO2 and re-
pressed by siNrf2 (Fig. 4 and supple-
mental Table S1). This gene subset
contained several previously char-
acterized Nrf2 target genes, including ferritin heavy chain 1
(FTH1), sequestosome 1 (SQSTM1), and glutathione reductase
(GSR), but the overall low number of genes indicates that other
Nrf2-independent pathways play a significant role inmediating
OA-NO2-dependent gene transcription.
Transcription Factor-binding Site Analyses—To define
other transcriptional pathways important for OA-NO2-de-
pendent gene regulation, transcriptomes were analyzed by
GSEA to assess whether certain transcription factor-binding
sites are over-represented within the promoter regions
of the genes elevated by OA-NO2 in comparison with OA-
treated and -untreated cells, respectively. In addition to Nrf2
and highly homologous MafG-binding sites, GSEA revealed
binding sites for cell stress-related transcription factors, spe-
cifically HSF1, HSF2, and AP1 (activator protein 1), which
were highly represented among OA-NO2-induced genes
(supplemental Table S2). In this analysis, 50% of enriched
transcription factor-binding sites were HSF-binding sites,
indicating that the HSR pathway is the most pronounced
response pathway in endothelial cells exposed to OA-NO2.
Detailed analysis revealed a large number of HSF1/2 target
genes within the OA-NO2-induced transcriptome, including
such well characterized HSF target genes as HSPA6 (heat
shock 70-kDa protein 6, also known as HSP70B), HSPA1A
(heat shock 70-kDa protein 1A, also known as HSP72,
HSPA1, HSP70I, HSPA1B, HSP70-1, and HSP70-1A), and
DNJA4 (DnaJ (Hsp40) homolog, subfamily A, member 4)
(Fig. 5 and supplemental Table S3). Of note, with the excep-
tion of HO-1, which has previously been shown to be regu-
lated by HSF1 on exposure to cadmium (33), silencing of
Nrf2 had no impact on basal or inducible expression of HSF1
FIGURE 2. InhibitionofNrf2blocksOA-NO2-inducedHO-1,GCLM, andNQO-1 expression.A,HUVECswere
transfected with 50 nM control or Nrf2 siRNA. 24 h after transfection, cells were treated with 3 M OA-NO2 for
8 h. The expression of Nrf2, HO-1, GCLM, and NQO1 was analyzed with quantitative real time PCR. ns, not
significant.B,HUVECswere transfectedwith50nMcontrol orNrf2 siRNAand24hafter transfection treatedwith
3 M OA-NO2. Cytoplasmic and nuclear extracts were isolated, and Nrf2 expression was analyzed by Western
blot analysis. Lamin B1was used as control for nuclear extracts. C,HUVECswere transfectedwith 50 nM control
or Nrf2 siRNA. 24 h after transfection, cells were treated with 3 M OA-NO2 for 16 h. The expression of HO-1,
GCLM, andNQO1was analyzedwithWesternblot. Values are expressed asmean S.E.,n 3. *,p 0.05 versus
control. Western blots are representative of three independent experiments.
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and HSF2 target genes (supplemental Fig. S4, A and B), indi-
cating that the OA-NO2-mediated HSR is independent of
Nrf2.
Validation ofMicroarray Data
Quantitative real time PCR was utilized to select for and val-
idate HSP genes showing the greatest induction by OA-NO2.
Incubation with 3 M OA-NO2 induced HSPA1A, DNAJA4,
HSPB8, and HSPA6mRNA in a time-dependent manner, with
maximum induction occurring at 4–8 h (Fig. 6A). Inasmuch as
HSPA1A (inducible HSP70) is the HSP most often used as an
indicator of HSR, HSP70 expression was also evaluated at the
protein level. OA-NO2 increased HSP70 protein in a concen-
tration- and time-dependent manner (Fig. 6, B and C). More-
over, OA-NO2 treatment of control or HSF1 siRNA-trans-
fected HUVECs revealed that HSF1-siRNA decreased HSF1
mRNA by 77% and HSF1 protein by 76%, quantified by densi-
tometry (Fig. 7,A andB). The silencing ofHSF1 caused a reduc-
tion of HSP70 expression at both mRNA (77%) and protein
(64%) levels, affirmingHSF-dependent regulation (Fig. 7,A and
B). Heat shock was used as a positive control in these experi-
ments. Similarly to OA-NO2, heat shock also induced HSP70
mRNA and protein significantly, and the expressions were
reduced in HSF1 siRNA-transfected cells by 85 and 81%,
respectively.
FIGURE 3. Hierarchical clustering of ANOVA signature genes. A, clustering of 363 ANOVA signature genes with significant intensity differences between
OA-NO2 (3M)-treated (n 6) andOA (3M)-treated cells (n 6). B, clustering of the top 50 genes with highest clustering ranks. The bar graph shows the fold
intensity differences between OA-NO2 and OA treatments, expressed as mean S.D. Asterisks represent heat shock-related genes.
FIGURE 4. Venn diagram of ANOVA signature genes. Genes with signif-
icant intensity differences either with 3 M OA-NO2 treatment or Nrf2-
specific siRNA were compared in a Venn diagram. The underlined numbers
indicate the number of genes regulated by each treatment alone or in
combination.1, up-regulation;2, down-regulation.
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Although HO-1 has a functional heat shock element in its
promoter (33) and is included in the GSEAHSF dataset (Fig. 5),
the suppression of HSF1 had no impact on HO-1 mRNA and
protein expression (supplemental Fig. S5). This indicates that
HSF1 does not regulate residualNrf2-independent induction of
HO-1 by OA-NO2 (Fig. 2). The OA-NO2 activation of HSF1
was also confirmed by the chromatin immunoprecipitation
analysis, which demonstrated increased binding of HSF1 to the
proximal HSP70 promoter (34) on exposure to OA-NO2 (Fig.
7C). Furthermore,Nrf2 silencing did not affect binding ofHSF1
to the HSP70 gene promoter (Fig. 7D), strengthening the
notion that HSF1 activation is Nrf2-independent.
DISCUSSION
Unsaturated fatty acids of membranes and lipoproteins
undergo both autocatalytic and enzymatically catalyzed per-
oxidation reactions yielding electrophilic derivatives that
include ,-unsaturated ketones, aldehydes, and nitroal-
kenes. Nitroalkenes are notable because the vinyl nitro group
confers a kinetically rapid and reversible electrophilic reactivity
that induces the post-translational modification of susceptible
proteins, principally via S-alkylation of thiols (35). Current data
support that cell survival and anti-inflammatory responses,
rather than dysmetabolic and genotoxic events, are predomi-
nantly evoked by low concentrations of electrophiles (36).Here,
genome-wide transcriptional profiling was utilized to identify
specific gene regulatory pathways that mediate vascular endo-
thelial responses to nitroalkenes. Suppression of Nrf2 transla-
tion supported that although phase II antioxidant responses are
induced by exposure to OA-NO2, there was also a robust acti-
vation of HSR-related gene expression. The expression of HSR
proteins are induced by a variety of stimuli, including heat,
exposure to chemicals and heavy metals, and oxidative inflam-
matorymediators. Various electrophiles have been shown to be
inducers ofHSR (37, 38). HSR is orchestrated byHSF transcrip-
FIGURE 5. OA-NO2 induces HSF target genes. Upon activation, HSF under-
goes a multistep process involving post-translational modifications, nuclear
enrichment, trimerization, and binding to heat shock elements resulting in
transcription of a large family of heat shock genes. The table shows HSF-
related, significantly regulated genes in the microarray after 3 M OA-NO2
treatment. Geneswere defined as HSF1 and -2 targets when an HSF1/2-bind-
ing site was present in the promoter region or an altered mRNA or protein
expression level has been reported in response to HSF1/2 activation. The
numbers at the right sides of the gene symbols indicate the fold differences
(FD) between the relativemRNA expression of OA-NO2- andOA-treated cells.
FIGURE 6. OA-NO2 induces heat shock response. A, HUVECs were treated
with 3MOA-NO2 for 0–24h, and theexpressionofHSPA1A,DNAJA4,HSPB8,
and HSPA6 was analyzed with quantitative real time PCR. Values are
expressed as mean S.E., n 3. *, p 0.05 versus control. B and C, HUVECs
were treated with 0–5MOA-NO2 for 8 h (B) or with 3MOA-NO2 for 0–24 h
(C). The expression of HSP70 was analyzed with Western blot.
Gene Expression Profiling in Response to Nitro-oleic Acid
33238 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 284•NUMBER 48•NOVEMBER 27, 2009
 at Vrije Universiteit, Medical Library, on December 21, 2011
w
w
w
.jbc.org
D
ow
nloaded from
 
tion factors, of which HSF1 is the most important in mediating
responses to cell stress (39). HSF activation and ensuing induc-
tion of HSP chaperones not only affords protection against the
adverse actions of misfolded proteins but also contributes to
the regulation of inflammatory processes (23).
Fatty acid nitroalkene derivatives mediate adaptive and
anti-inflammatory signaling via mechanisms frequently cen-
tered on post-translational protein modification of suscep-
tible signaling mediators by electrophiles (40). This includes
inhibition of NF-B-dependent signaling (7) that in turn
leads to protection against ischemic injury (3), activation
of peroxisome proliferator-activated receptor -dependent
gene expression (41), and inhibition of inflammatory cell func-
tion (7, 42). Also, lipopolysaccharide-induced STAT1 (signal
transducer and activator of transcription 1) phosphorylation
and the STAT1-dependent transcription are inhibited, thereby
suppressing expression of the pro-inflammatory target genes
inducible nitric-oxide synthase and
MCP-1 (43). Induction of HSP ex-
pression adds to these operative
mechanisms, as HSF1-dependent
HSP70 expression attenuates NF-
B-dependent gene expression
and signaling via HSP70 interac-
tion with the IB kinase (44). In
addition, HSP27 (HSPB1), signifi-
cantly induced by OA-NO2, simi-
larly inhibits NF-B activity (45).
Notably, both heat shock and
HSF-activating agents, as well as
OA-NO2, protect kidneys from
ischemia-reperfusion injury (46–
48), supporting the notion that
HSF-mediated anti-inflammatory
actions of OA-NO2 may play a role
in the protection against ischemia-
reperfusion injury.
In addition to inhibiting inflam-
mation, the HSR provides addi-
tional benefit to vascular endothe-
lium. Endothelial cell injury is a
critical component of atherosclero-
sis, thrombosis, and neointimal pro-
liferation (49). HSPs display diverse
cytoprotective functions, with heat
shock pre-conditioning protecting
against the cytotoxic effects of hy-
drogen peroxide in human endo-
thelial cells (23, 50). Although the
soluble plasma HSP60 may induce
pro-atherogenic effects, intracellu-
lar HSPs are typically athero-pro-
tective (51). HSF1 also contributes
to the statin-induced regulation of
expression of the thrombin inhib-
itor thrombomodulin and the net
antithrombotic effects of the HSR
(52).
The detailed mechanism whereby OA-NO2 stimulates the
HSR remains a matter of investigation, with HSF activation
viewed to be an initial signaling event (39). On activation, HSFs
trimerize and bind to heat shock elements, consisting of repet-
itive nGAAn sequences in target genes such as HSPs. Although
stress-induced phosphorylation and other post-translational
modifications of HSF contribute to activation via trimerization
(39, 53), other mechanisms may also be operative. HSF1 con-
tains redox-sensitive cysteine residues that are apparently oxi-
dized by hydrogen peroxide to reversibly assemble into a
homotrimer (54). It is therefore conceivable that electrophiles
such as OA-NO2 can adduct and activate HSF1-dependent
gene expression via adduction of these residues. Also, electro-
philic lipid peroxidation products such as 4-hydroxynonenal
bind to many heat shock proteins (e.g.HSP70 and HSP90) (55),
with HSP90 cysteine 572 being exceptionally sensitive to thiol
modification (56). Inasmuch as OA-NO2 is known to target
FIGURE 7. OA-NO2 induces HSP70 expression via HSF1. A and B, HUVECs were transfected with 100 nM
control or HSF1 siRNA. 72 h after transfection, cells were treated with 3MOA-NO2 for 4 h (A) or 8 h (B) or with
heat shock for 30min. The expression levels ofHSF1 and HSP70 (HSPA1A) were analyzedwith quantitative real
time PCR (A) orWestern blot (B). Values are expressed asmean S.E., n 3. *, p 0.05 versus control. Western
blots are representative of three independent experiments. C,HUVECswere treatedwith 5MOA-NO2 for 4 h.
The binding of HSF1 to the promoter region of HSP70 was determined with chromatin immunoprecipitation
using-actin as a control.D,HUVECswere transfectedwith 50 nM control or Nrf2 siRNA. 72 h after transfection,
cells were treated with OA-NO2 for 4 h. The binding of HSF1 to the promoter region of HSP70 was determined
with chromatin immunoprecipitation using -actin as a control.
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cysteine residues in proteins (4), OA-NO2 may well adduct
these chaperones and other redox-sensitive proteins involved
in protein folding and turnover in an analogous manner,
thereby alteringHSP function and inducing compensatory acti-
vation of the HSR pathway. It is notable that interactions of
HSF1 with HSP70 and HSP90 maintains it in an inactive
state (57) and that modification of these co-chaperones can
abolish their repressive functions. In support of the concept
that post-translational modification of HSP70 can facilitate
HSF1 activation by electrophilic lipids, the interaction of
HSP70 with HSF1 is inhibited by 4-hydroxynonenal (37).
A critical insight from this study is the observation that
the heat shock response is not dependent on Nrf2. Con-
versely, silencing of HSF1, important for HO-1 induction by
cadmium exposure (33), had no impact on HO-1 expression
in this study. The residual Nrf2-independent induction of
HO-1may involve a number of potential regulators, as the tran-
scriptional regulation of HO-1 is complex (58). Upon exposure
to oxidized phospholipids, bothNrf2 and the cAMP-responsive
element-binding protein mediate HO-1 induction in human
endothelial cells (25, 59). Genome-wide transcriptional profil-
ing of HSF1 target genes usingHSF1-null mouse fibroblasts did
not show an induction of known ARE target genes (60), further
supporting that these two stress responses are distinct and sep-
arate. However, the molecular attributes important for biolog-
ical responses may be similar for both pathways. For example,
the actions of the HSF1 activator celastrol, a quinone methide
triterpene-based traditional Chinese medicinal herb, can be
blocked by an added excess of thiol (61). The effects of celastrol
that are blocked by thiols not only include triggering HSR but
also inhibition of glucocorticoid receptor activity andARE acti-
vation (61).
In summary, the exemplary nitroalkene fatty acid derivative
OA-NO2 is a potent inducer of the HSR, adding a new dimen-
sion to the pleiotropic anti-inflammatory signaling mecha-
nisms manifested by these products of oxidative inflammatory
reactions (2, 40, 62). The small molecule activation of the HSR
is an emerging therapeutic modality for a number of human
diseases affecting protein folding and conformation, as well as
inflammatory conditions such as ischemia-reperfusion injury
(23). Electrophilic fatty acid nitroalkenes, in this context, thus
represent a new class of potent HSR inducers. It is noteworthy
that the effective concentrations ofOA-NO2 sufficient to evoke
HSR are comparable with the most efficacious HSR activators
currently available, with the exception of some HSP90 inhibi-
tors (23), suggesting that this biological activity is achievable
in vivo.
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